{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:19:59Z","timestamp":1793841599403,"version":"4.6.1"},"reference-count":141,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune-related adverse events (irAEs) are a range of complications associated with the use of immune-checkpoint inhibitors (ICIs). Two major classes of ICIs widely used are Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) and Programmed Cell death-1 (PD-1)\/Programmed death-ligand 1 (PD-L1) inhibitors. High-grade irAEs are life-threatening and often cause a severe decline in performance status in such that patients do not qualify for any further anticancer treatments. It is difficult to generalize the evidence in the current literature on risk factors or biomarkers for the entire class of ICIs as the studies so far are either disease-specific (e.g., lung cancer or melanoma) or ICI agent-specific (e.g., pembrolizumab, ipilimumab) or irAE-specific (e.g., pneumonitis or gastritis). In this review, risk factors and biomarkers to consider before initiating or monitoring ICI are listed with a practical purpose in day-to-day practice. Risk factors are grouped into demographics and social history, medical history, and medication history, tumor-specific and agent-specific risk factors. A higher risk of irAE is associated with age &amp;lt;60 years, high body mass index, women on CTLA4 and men on PD-1\/PD-L1 agents, and chronic smokers. Patients with significant kidney (Stage IV-V), cardiac (heart failure, coronary artery disease, myocardial infarction, hypertension), and lung (asthma, pulmonary fibrosis, and chronic obstructive pulmonary disease) are at a higher risk of respective organ-specific irAEs. Pre-existing autoimmune disease and chronic use of certain drugs (proton pump inhibitors, diuretics, anti-inflammatory drugs) also increase the irAE-risk. Biomarkers are categorized into circulating blood counts, cytokines, autoantibodies, HLA genotypes, microRNA, gene expression profiling, and serum proteins. The blood counts and certain protein markers (albumin and thyroid-stimulating hormone) are readily accessible in current practice. High neutrophil-lymphocyte ratio, eosinophil\/monocyte\/lymphocyte counts; TSH and troponins at diagnosis and drop in the white count and lymphocyte count can predict irAE. Other biomarkers with limited evidence are cytokines, autoantibodies, HLA genotypes, microRNA, and gene expression profiling. With fast-expanding approvals for ICIs in various cancer types, knowledge on risk factors and biomarkers can help providers assess the irAE-risk of their patients. Prospective disease and agent-specific studies are needed to provide further insight on this essential aspect of ICI therapy.<\/jats:p>","DOI":"10.3389\/fimmu.2022.779691","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T14:44:14Z","timestamp":1663944254000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":332,"title":["Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors"],"prefix":"10.3389","volume":"13","author":[{"given":"Adithya","family":"Chennamadhavuni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laith","family":"Abushahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn J.","family":"Presley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Manne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3390\/cancers12030738","article-title":"Review of Indications of FDA-Approved Immune Checkpoint Inhibitors Per NCCN Guidelines With the Level of Evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx440.011","article-title":"LBA18 - Efficacy of BMS-986016, a Monoclonal Antibody That Targets Lymphocyte Activation Gene-3 (LAG-3), in Combination With Nivolumab in Pts With Melanoma Who Progressed During Prior Anti\u2013PD-1\/PD-L1 Therapy (Mel Prior IO) in All-Comer and Biomarker-Enriched Populations","volume":"28","author":"Ascierto","year":"2017","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1172\/JCI81187","article-title":"TIGIT Predominantly Regulates the Immune Response via Regulatory T Cells","volume":"125","author":"Kurtulus","year":"2015","journal-title":"J Clin Invest"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0096","article-title":"Anti-TIM3 Antibody Promotes T Cell IFN-\u03b3\u2013Mediated Antitumor Immunity and Suppresses Established Tumors","volume":"71","author":"Ngiow","year":"2011","journal-title":"Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.104","article-title":"Preliminary Results of a Phase I\/IIa Study of BMS-986156 (Glucocorticoid-Induced Tumor Necrosis Factor Receptor\u2013Related Gene [GITR] Agonist), Alone and in Combination With Nivolumab in Pts With Advanced Solid Tumors","volume":"35","author":"Siu","year":"2017","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.2521","article-title":"Dose Escalation Results From a First-In-Human, Phase 1 Study of the Glucocorticoid-Induced TNF Receptor-Related Protein (GITR) Agonist AMG 228 in Patients (Pts) With Advanced Solid Tumors","volume":"35","author":"Tran","year":"2017","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1259","article-title":"Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes With Pi3k\u03b2 Inhibition in PTEN Loss Melanoma","volume":"25","author":"Peng","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/s41467-021-21383-1","article-title":"Neoadjuvant Anti-OX40 (MEDI6469) Therapy in Patients With Head and Neck Squamous Cell Carcinoma Activates and Expands Antigen-Specific Tumor-Infiltrating T Cells","volume":"12","author":"Duhen","year":"2021","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI123955","article-title":"Blocking Expression of Inhibitory Receptor NKG2A Overcomes Tumor Resistance to NK Cells","volume":"129","author":"Kamiya","year":"2019","journal-title":"J Clin Invest"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan5488","article-title":"Enhanced Preclinical Antitumor Activity of M7824, a Bifunctional Fusion Protein Simultaneously Targeting PD-L1 and TGF-\u03b2","volume":"10","author":"Lan","year":"2018","journal-title":"Sci Trans Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.042762","article-title":"The T-Cell-Receptor Signaling Network","volume":"122","author":"Huse","year":"2009","journal-title":"J Cell Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 Regulates the Development, Maintenance, and Function of Induced Regulatory T Cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J Exp Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"111ra120","DOI":"10.1126\/scitranslmed.3003130","article-title":"The PDL1-PD1 Axis Converts Human TH1 Cells Into Regulatory T Cells","volume":"3","author":"Amarnath","year":"2011","journal-title":"Sci Transl Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nri3108","article-title":"The Emerging Role of CTLA4 as a Cell-Extrinsic Regulator of T Cell Responses","volume":"11","author":"Walker","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular Carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01549-2","article-title":"Are Immune-Related Adverse Events Associated With the Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer? A Systematic Review and Meta-Analysis","volume":"18","author":"Zhou","year":"2020","journal-title":"BMC Med"},{"key":"B17","volume-title":"Common Terminology Criteria for Adverse Events: (CTCAE) V5.0","year":"2017"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13541","article-title":"Meta-Analysis of Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy in Cancer Patients","volume":"11","author":"Song","year":"2020","journal-title":"Thorac Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"108377","DOI":"10.1016\/j.clim.2020.108377","article-title":"Immune-Related Adverse Events of Checkpoint Inhibitors: Insights Into Immunological Dysregulation","volume":"213","author":"Yang","year":"2020","journal-title":"Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez308","article-title":"Mechanisms of Immune-Related Adverse Events During the Treatment of Cancer With Immune Checkpoint Inhibitors","volume":"58","author":"Weinmann","year":"2019","journal-title":"Rheumatology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and Class-Specific Patterns of Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3747\/co.25.4047","article-title":"Predictors of Immunotherapy-Induced Immune-Related Adverse Events","volume":"25","author":"Kartolo","year":"2018","journal-title":"Curr Oncol (Toronto Ont)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.03.020","article-title":"Predictive Value of Serum Protein Levels in Patients With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab","volume":"132","author":"Oyanagi","year":"2019","journal-title":"Lung Cancer"},{"key":"B24","doi-asserted-by":"crossref","DOI":"10.14740\/jocmr4511","article-title":"Clinical and Hematological Predictors of High-Grade Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors","volume-title":"J Clin Med Res","author":"Manne","year":"2021"},{"key":"B25","article-title":"Fatal Adverse Events Associated With Pembrolizumab in Cancer Patients: A Meta-Analysis","volume-title":"Cancer Investigation","author":"AF","year":"2020"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0563","article-title":"Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated With Immune-Checkpoint Inhibitors","volume":"24","author":"A","year":"2019","journal-title":"Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1579","article-title":"Risk Factors for Pneumonitis in Patients Treated With Anti-Programmed Death-1 Therapy: A Case-Control Study","volume":"7","author":"Cui","year":"2018","journal-title":"Cancer Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.15_suppl.2505","article-title":"Evaluation of Serum IL-17 Levels During Ipilimumab Therapy: Correlation With Colitis","volume":"29","author":"Callahan","year":"2011","journal-title":"J Clin Oncol"},{"key":"B29","article-title":"Risk Factors: Definitions and Practical Implications","volume":"24","author":"Vaz","year":"2005","journal-title":"Rev Port Cardiol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1159\/000512633","article-title":"The Risk Factors Associated With Immune Checkpoint Inhibitor-Related Pneumonitis","volume":"99","author":"Asada","year":"2021","journal-title":"Oncology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"102590","DOI":"10.1016\/j.autrev.2020.102590","article-title":"Immune Checkpoint Inhibitors-Induced Autoimmunity: The Impact of Gender","volume":"19","author":"Triggianese","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-021-00106-x","article-title":"A Retrospective Analysis of Cardiovascular Adverse Events Associated With Immune Checkpoint Inhibitors","volume":"7","author":"Lal","year":"2021","journal-title":"Cardio-Oncology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1467-x","article-title":"Sex and Interleukin-6 Are Prognostic Factors for Autoimmune Toxicity Following Treatment With Anti-CTLA4 Blockade","volume":"16","author":"Valpione","year":"2018","journal-title":"J Trans Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1700050","DOI":"10.1183\/13993003.00050-2017","article-title":"Immune-Checkpoint Inhibitors Associated With Interstitial Lung Disease in Cancer Patients","volume":"50","author":"Delaunay","year":"2017","journal-title":"Eur Respir J"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-70743-2","article-title":"Risk Factors of Immune Checkpoint Inhibitor-Related Interstitial Lung Disease in Patients With Lung Cancer: A Single-Institution Retrospective Study","volume":"10","author":"Okada","year":"2020","journal-title":"Sci Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13703","article-title":"Immune-Related Adverse Events in Cancer Patients Being Treated With Immune Checkpoint Inhibitors","volume":"107","author":"Byrne","year":"2021","journal-title":"Eur J Haematol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-50574-6","article-title":"Risk Factors for Immune-Related Adverse Events Associated With Anti-PD-1 Pembrolizumab","volume":"9","author":"Eun","year":"2019","journal-title":"Sci Rep"},{"key":"B38","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00262-020-02663-z","article-title":"Body Mass Index and Immune-Related Adverse Events in Patients on Immune Checkpoint Inhibitor Therapies: A Systematic Review and Meta-Analysis","volume":"70","author":"Guzman-Prado","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-20-1362","article-title":"Metabolic Disease and Adverse Events From Immune Checkpoint Inhibitors","volume":"184","author":"Leiter","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.431","article-title":"The Impact of Body Composition Parameters on Ipilimumab Toxicity and Survival in Patients With Metastatic Melanoma","volume":"116","author":"Daly","year":"2017","journal-title":"Br J Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-88307-3","article-title":"Association of Blood Biomarkers and Autoimmunity With Immune Related Adverse Events in Patients With Cancer Treated With Immune Checkpoint Inhibitors","volume":"11","author":"Michailidou","year":"2021","journal-title":"Sci Rep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01430","article-title":"PD-1 Inhibitor Immune-Related Adverse Events in Patients With Preexisting Endocrine Autoimmunity","volume":"103","author":"Akturk","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders or Major Toxicity With Ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0861","article-title":"Analysis of Risk Factors for Immune-Related Adverse Events in Various Solid Tumors Using Real-World Data","volume":"17","author":"Shimozaki","year":"2021","journal-title":"Future Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0498","article-title":"FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1","volume":"21","author":"Sul","year":"2016","journal-title":"Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12759","article-title":"Efficacy and Safety of Nivolumab in Non-Small Cell Lung Cancer With Preexisting Interstitial Lung Disease","volume":"9","author":"Kanai","year":"2018","journal-title":"Thorac Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00262-019-02431-8","article-title":"Association of Immune-Related Pneumonitis With the Presence of Preexisting Interstitial Lung Disease in Patients With Non-Small Lung Cancer Receiving Anti-Programmed Cell Death 1 Antibody","volume":"69","author":"Shibaki","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.02.032","article-title":"Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer","volume":"160","author":"Atchley","year":"2021","journal-title":"Chest"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13736","article-title":"Outcome and Risk Factor of Immune-Related Adverse Events and Pneumonitis in Patients With Advanced or Postoperative Recurrent Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors","volume":"12","author":"Isono","year":"2021","journal-title":"Thorac Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-01002-w","article-title":"Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors","volume":"23","author":"Pirozzi","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical Features and Outcomes of Immune Checkpoint Inhibitor\u2013Associated AKI: A Multicenter Study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1053\/j.ajkd.2019.07.012","article-title":"Proton Pump Inhibitors and the Kidney: Implications of Current Evidence for Clinical Practice and When and How to Deprescribe","volume":"75","author":"Al-Aly","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1991.tb03743.x","article-title":"Nonsteroidal Anti-Inflammatory Drugs: Effects on Kidney Function","volume":"31","author":"Whelton","year":"1991","journal-title":"J Clin Pharmacol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00990119","article-title":"The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"16","DOI":"10.34067\/KID.0000152019","article-title":"Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy","volume":"1","author":"Manohar","year":"2020","journal-title":"Kidney360"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients","volume":"68","author":"Shirali","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000467","article-title":"Acute Kidney Injury Associated With Immune Checkpoint Inhibitor Therapy: Incidence, Risk Factors and Outcomes","volume":"8","author":"Meraz-Mu\u00f1oz","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003779","article-title":"Association of Antibiotic Treatment With Immune-Related Adverse Events in Patients With Cancer Receiving Immunotherapy","volume":"10","author":"Jing","year":"2022","journal-title":"J ImmunoTher Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01504","article-title":"Human Memory Th17 Cell Populations Change Into Anti-Inflammatory Cells With Regulatory Capacity Upon Exposure to Active Vitamin D","volume":"10","author":"Dankers","year":"2019","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.05020-11","article-title":"1,25-Dihydroxyvitamin D(3) Ameliorates Th17 Autoimmunity via Transcriptional Modulation of Interleukin-17a","volume":"31","author":"Joshi","year":"2011","journal-title":"Mol Cell Biol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0353-7","article-title":"Influenza Vaccination of Cancer Patients During PD-1 Blockade Induces Serological Protection But May Raise the Risk for Immune-Related Adverse Events","volume":"6","author":"L\u00e4ubli","year":"2018","journal-title":"J ImmunoTher Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.02.011","article-title":"The Association Between Tumor Burden and Severe Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Responding to Immune-Checkpoint Inhibitor Treatment","volume":"130","author":"Sakata","year":"2019","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1001\/jamaoncol.2019.3221","article-title":"Association Between Immune-Related Adverse Events During Anti\u2013PD-1 Therapy and Tumor Mutational Burden","volume":"5","author":"Bomze","year":"2019","journal-title":"JAMA Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.01.010","article-title":"Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies","volume":"21","author":"Gesiotto","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.02.401","article-title":"Epidemiology and Risk Factors for the Development of Cutaneous Toxicities in Patients Treated With Immune-Checkpoint Inhibitors: A United States Population-Level Analysis","author":"Wongvibulsin","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B66","doi-asserted-by":"crossref","DOI":"10.1002\/onco.13740","article-title":"Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study From 2011 to 2018","volume-title":"The Oncologist","author":"Molina","year":"2021"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-021-10151-4","article-title":"Checkpoint Inhibitor Induced Hepatitis and the Relation With Liver Metastasis and Outcome in Advanced Melanoma Patients","volume":"15","author":"Biewenga","year":"2021","journal-title":"Hepatol Int"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.03.012","article-title":"The Effect of Adding Immune Checkpoint Inhibitors on the Risk of Pneumonitis for Solid Tumours: A Meta-Analysis of Phase III Randomised Controlled Trials","volume":"150","author":"Fujiwara","year":"2021","journal-title":"Eur J Cancer"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab035","article-title":"Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy","volume":"113","author":"Jing","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000871","article-title":"Impact of Age on the Toxicity of Immune Checkpoint Inhibition","volume":"8","author":"Samani","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"B71","first-page":"57","article-title":"[Evaluation of Risk Factors for Immune-Related Adverse Events Associated With Treatment With Immune Checkpoint Inhibitors]","volume":"48","author":"Aimono","year":"2021","journal-title":"Gan To Kagaku Ryoho"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001935","article-title":"Prediction of Severe Immune-Related Adverse Events Requiring Hospital Admission in Patients on Immune Checkpoint Inhibitors: Study of a Population Level Insurance Claims Database From the USA","volume":"9","author":"Kalinich","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.786046","article-title":"Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy","volume":"12","author":"Wong","year":"2021","journal-title":"Front Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0450","article-title":"Impact of Age on Outcomes With Immunotherapy for Patients With Melanoma","volume":"22","author":"Betof","year":"2017","journal-title":"Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-021-00112-z","article-title":"Prognostic Impact of Immune-Related Adverse Events on Patients With and Without Cardiovascular Disease: A Retrospective Review","volume":"7","author":"Kazama","year":"2021","journal-title":"Cardio-Oncology"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of Programmed Death\u20131 Pathway Inhibitors Among Patients With Non\u2013Small-Cell Lung Cancer and Preexisting Autoimmune Disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J Clin Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01674","article-title":"Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease","volume":"38","author":"Abu-Sbeih","year":"2020","journal-title":"J Clin Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.625872","article-title":"The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease","volume":"11","author":"Tang","year":"2021","journal-title":"Front Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00137","article-title":"Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders","volume":"7","author":"Coureau","year":"2020","journal-title":"Front Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.7039","article-title":"Association of Medical Comorbidities and Cardiovascular Disease With Toxicity and Survival in Patients Receiving Checkpoint Inhibitor Immunotherapy","volume":"38","author":"Johns","year":"2020","journal-title":"J Clin Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.07.031","article-title":"Immune-Related Adverse Events and Kidney Function Decline in Patients With Genitourinary Cancers Treated With Immune Checkpoint Inhibitors","volume":"157","author":"Seethapathy","year":"2021","journal-title":"Eur J Cancer"},{"key":"B82","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ejca.2021.01.005","article-title":"Renal Adverse Effects of Immune Checkpoints Inhibitors in Clinical Practice: ImmuNoTox Study","volume":"147","author":"Espi","year":"2021","journal-title":"Eur J Cancer"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-1004","article-title":"Incidence, Predictors and 6-Month Overall Outcome of Acute Kidney Injury in Chinese Patients Receiving PD-1 Inhibitors0","author":"Qin","year":"2022","journal-title":"Future Oncol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-020-02094-x","article-title":"Vitamin D, Autoimmunity and Immune-Related Adverse Events of Immune Checkpoint Inhibitors","volume":"313","author":"Sun","year":"2021","journal-title":"Arch Dermatol Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz202","article-title":"Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors","volume":"70","author":"Chong","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.09.012","article-title":"Influenza Vaccination in Patients With Lung Cancer Receiving Anti-Programmed Death Receptor 1 Immunotherapy Does Not Induce Immune-Related Adverse Events","volume":"104","author":"Wijn","year":"2018","journal-title":"Eur J Cancer"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000788","article-title":"Vaccination and Immune Checkpoint Inhibitors: Does Vaccination Increase the Risk of Immune-Related Adverse Events? A Systematic Review of Literature","volume":"44","author":"Desage","year":"2021","journal-title":"Am J Clin Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000415","article-title":"Association of Blood Biochemical Indexes and Antibiotic Exposure With Severe Immune-Related Adverse Events in Patients With Advanced Cancers Receiving PD-1 Inhibitors","volume":"45","author":"Zhao","year":"2022","journal-title":"J Immunother"},{"key":"B89","unstructured":"BEST (Biomarkers, EndpointS, and Other Tools) Resource. Silver Spring (MD): Food and Drug Administration (US); Bethesda (MD): National Institutes of Health (Us)2016"},{"key":"B90","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.lungcan.2020.08.015","article-title":"Association of Baseline Peripheral-Blood Eosinophil Count With Immune Checkpoint Inhibitor-Related Pneumonitis and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors","volume":"150","author":"Chu","year":"2020","journal-title":"Lung Cancer"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyy201","article-title":"Correlation Between Blood Cell Count and Outcome of Melanoma Patients Treated With Anti-PD-1 Antibodies","volume":"49","author":"Nakamura","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.3390\/cancers13061308","article-title":"Neutrophil-To-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes From Immune Checkpoint Blockade: A Case-Control Study","volume":"13","author":"Lee","year":"2021","journal-title":"Cancers"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline Gut Microbiota Predicts Clinical Response and Colitis in Metastatic Melanoma Patients Treated With Ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1611421113","article-title":"Clonal Expansion of CD8 T Cells in the Systemic Circulation Precedes Development of Ipilimumab-Induced Toxicities","volume":"113","author":"Subudhi","year":"2016","journal-title":"Proc Natl Acad Sci"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2324","article-title":"Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated With Early Diversification of the T-Cell Repertoire","volume":"77","author":"Oh","year":"2017","journal-title":"Cancer Res"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2017.07.007","article-title":"Fluctuations in Routine Blood Count Might Signal Severe Immune-Related Adverse Events in Melanoma Patients Treated With Nivolumab","volume":"88","author":"Fujisawa","year":"2017","journal-title":"J Dermatol Sci"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-SITC2020.0648","article-title":"Cytokine Changes During Immune-Related Adverse Events and Corticosteroid Treatment in Melanoma Patients Receiving Immune Checkpoint Inhibitors","volume":"8","author":"Tyan","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.4110\/in.2020.20.e27","article-title":"Baseline Serum Interleukin-6 Levels Predict the Response of Patients With Advanced Non-Small Cell Lung Cancer to PD-1\/PD-L1 Inhibitors","volume":"20","author":"Kang","year":"2020","journal-title":"Immune Netw"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0155-1","article-title":"Immune Dysregulation in Cancer Patients Developing Immune-Related Adverse Events","volume":"120","author":"Khan","year":"2019","journal-title":"Br J Cancer"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2795","article-title":"Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1\u2013Based Immunotherapy","volume":"25","author":"Lim","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24509","article-title":"Serum Levels of Soluble CD163 and CXCL5 May Be Predictive Markers for Immune-Related Adverse Events in Patients With Advanced Melanoma Treated With Nivolumab: A Pilot Study","volume":"9","author":"Fujimura","year":"2018","journal-title":"Oncotarget"},{"key":"B102","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40425-015-0081-1","article-title":"Baseline Circulating IL-17 Predicts Toxicity While TGF-Beta1 and IL-10 Are Prognostic of Relapse in Ipilimumab Neoadjuvant Therapy of Melanoma","volume":"3","author":"Tarhini","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13832","article-title":"The Levels of Interferon-Gamma Release as a Biomarker for Non-Small-Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors","volume":"39","author":"Hirashima","year":"2019","journal-title":"Anticancer Res"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-019-03002-1","article-title":"C-Reactive Protein as an Early Marker of Immune-Related Adverse Events","volume":"145","author":"Abolhassani","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00262-018-2258-1","article-title":"Soluble CTLA-4 as a Favorable Predictive Biomarker in Metastatic Melanoma Patients Treated With Ipilimumab: An Italian Melanoma Intergroup Study","volume":"68","author":"Pistillo","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1908079116","article-title":"Autoimmune Antibodies Correlate With Immune Checkpoint Therapy-Induced Toxicities","volume":"116","author":"Tahir","year":"2019","journal-title":"Proc Natl Acad Sci"},{"key":"B107","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1001\/jamaoncol.2018.5860","article-title":"Profiling Preexisting Antibodies in Patients Treated With Anti\u2013PD-1 Therapy for Advanced Non\u2013Small Cell Lung Cancer","volume":"5","author":"Toi","year":"2019","journal-title":"JAMA Oncol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2020.906","article-title":"Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated With PD-1\/PD-L1 Inhibitors","volume":"36","author":"Yoon","year":"2021","journal-title":"Endocrinol Metab"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-021-01508-5","article-title":"Higher Baseline TSH Levels Predict Early Hypothyroidism During Cancer Immunotherapy","volume":"44","author":"Luongo","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01480-6","article-title":"Baseline Serum TSH Levels Predict the Absence of Thyroid Dysfunction in Cancer Patients Treated With Immunotherapy","volume":"44","author":"Brilli","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2016.09.030","article-title":"Relevance of Serum Biomarkers Associated With Melanoma During Follow-Up of Anti-CTLA-4 Immunotherapy","volume":"40","author":"Felix","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.045","article-title":"BP180-Specific IgG is Associated With Skin Adverse Events, Therapy Response, and Overall Survival in Non-Small Cell Lung Cancer Patients Treated With Checkpoint Inhibitors","volume":"82","author":"Hasan Ali","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2018.11.009","article-title":"Human Leukocyte Antigen Variation Is Associated With Adverse Events of Checkpoint Inhibitors","volume":"107","author":"Hasan Ali","year":"2019","journal-title":"Eur J Cancer"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.2337\/dbi18-0002","article-title":"Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"B115","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ejca.2020.02.049","article-title":"Human Leucocyte Antigen DR15, a Possible Predictive Marker for Immune Checkpoint Inhibitor-Induced Secondary Adrenal Insufficiency","volume":"130","author":"Yano","year":"2020","journal-title":"Eur J Cancer"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key358","article-title":"Association of HLA-DRB1 Shared Epitope Alleles and Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis","volume":"58","author":"Cappelli","year":"2019","journal-title":"Rheumatology"},{"key":"B117","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3803\/EnM.2021.1282","article-title":"Human Leukocyte Antigens and Biomarkers in Type 1 Diabetes Mellitus Induced by Immune-Checkpoint Inhibitors","volume":"37","author":"Inaba","year":"2022","journal-title":"Endocrinol Metab (Seoul)"},{"key":"B118","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1479-5876-11-75","article-title":"Gene Expression Profiling of Whole Blood in Ipilimumab-Treated Patients for Identification of Potential Biomarkers of Immune-Related Gastrointestinal Adverse Events","volume":"11","author":"Shahabi","year":"2013","journal-title":"J Trans Med"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.132334","article-title":"MicroRNA-146a Regulates Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors","volume":"5","author":"Marschner","year":"2020","journal-title":"JCI Insight"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02797-0","article-title":"Genetic Determinants of Immune-Related Adverse Events in Patients With Melanoma Receiving Immune Checkpoint Inhibitors","volume":"70","author":"Abdel-Wahab","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B121","doi-asserted-by":"publisher","first-page":"10391","DOI":"10.1038\/ncomms10391","article-title":"Intestinal Microbiome Analyses Identify Melanoma Patients at Risk for Checkpoint-Blockade-Induced Colitis","volume":"7","author":"Dubin","year":"2016","journal-title":"Nat Commun"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13990","article-title":"Clinical-Radiological Characteristics and Intestinal Microbiota in Patients With Pancreatic Immune-Related Adverse Events","volume":"12","author":"Tan","year":"2021","journal-title":"Thorac Cancer"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0577-1","article-title":"Early Introduction of Selective Immunosuppressive Therapy Associated With Favorable Clinical Outcomes in Patients With Immune Checkpoint Inhibitor\u2013Induced Colitis","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"J ImmunoTher Cancer"},{"key":"B124","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-018-0411-1","article-title":"Importance of Endoscopic and Histological Evaluation in the Management of Immune Checkpoint Inhibitor-Induced Colitis","volume":"6","author":"Abu-Sbeih","year":"2018","journal-title":"J ImmunoTher Cancer"},{"key":"B125","doi-asserted-by":"publisher","first-page":"534","DOI":"10.12688\/f1000research.53327.1","article-title":"Fecal Calprotectin as a Predictor of Gastrointestinal Immune-Related Adverse Events (CF-19): A Prospective Study","volume":"10","author":"Carde\u00f1a Guti\u00e9rrez","year":"2021","journal-title":"F1000Research"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002058","article-title":"Fecal Calprotectin Concentration to Assess Endoscopic and Histologic Remission in Patients With Cancer With Immune-Mediated Diarrhea and Colitis","volume":"9","author":"Zou","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v7.i4.405","article-title":"Immune Checkpoint Inhibitor-Induced Colitis: A Comprehensive Review","volume":"7","author":"Som","year":"2019","journal-title":"World J Clin Cases"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.292","article-title":"A Derived Neutrophil to Lymphocyte Ratio Predicts Survival in Patients With Cancer","volume":"107","author":"Proctor","year":"2012","journal-title":"Br J Cancer"},{"key":"B129","article-title":"[Predictors of Nivolumab-Induced Skin Reactions]","volume":"45","author":"T","year":"2018","journal-title":"Gan  Kagaku Ryoho Cancer Chemother"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0682","article-title":"IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity From Immunotherapy","volume":"7","author":"Johnson","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B131","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/B978-0-12-374279-7.06013-6","article-title":"HLA and Autoimmunity","volume-title":"Encyclopedia of Immunobiology","author":"Gehlot","year":"2016"},{"key":"B132","article-title":"Human Leukocyte Antigen (HLA) Typing by DNA Sequencing","volume-title":"Methods in Molecular Biology","author":"Lazaro","year":"2013"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1712901115","article-title":"Bifidobacterium can Mitigate Intestinal Immunopathology in the Context of CTLA-4 Blockade","volume":"115","author":"Wang","year":"2018","journal-title":"Proc Natl Acad Sci"},{"key":"B134","unstructured":"Management of Immunotherapy - Related Toxicities2021"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3390\/cancers14040955","article-title":"Safety of Immune Checkpoint Inhibitor Resumption After Interruption for Immune-Related Adverse Events, a Narrative Review","volume":"14","author":"Allouchery","year":"2022","journal-title":"Cancers"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001622","article-title":"Safety of Immune Checkpoint Inhibitor Rechallenge After Discontinuation for Grade \u22652 Immune-Related Adverse Events in Patients With Cancer","volume":"8","author":"Allouchery","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.08.063","article-title":"AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review","volume":"160","author":"Dougan","year":"2021","journal-title":"Gastroenterology"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.107","article-title":"Efficacy and Toxicity of Treatment With the Anti-CTLA-4 Antibody Ipilimumab in Patients With Metastatic Melanoma After Prior Anti-PD-1 Therapy","volume":"114","author":"Bowyer","year":"2016","journal-title":"Br J Cancer"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx642","article-title":"Safety of Resuming Anti-PD-1 in Patients With Immune-Related Adverse Events (irAEs) During Combined Anti-CTLA-4 and Anti-PD1 in Metastatic Melanoma","volume":"29","author":"Pollack","year":"2018","journal-title":"Ann Oncol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0755","article-title":"Safety and Efficacy of Re-Treating With Immunotherapy After Immune-Related Adverse Events in Patients With NSCLC","volume":"6","author":"Santini","year":"2018","journal-title":"Cancer Immunol Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.779691\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T14:44:26Z","timestamp":1663944266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.779691\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,26]]},"references-count":141,"alternative-id":["10.3389\/fimmu.2022.779691"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.779691","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,26]]},"article-number":"779691"}}